The data were presented in detail at the recent American College of Chest Physicians (CHEST) annual meeting.
The first paper assessed the performance of the EarlyCDT Lung blood test in PANOPTIC clinical trial samples to identify potentially malignant indeterminate pulmonary nodules (growths in the lung).
The reported specificity was 93% and positive predictive value 74%, which Oncimmune said correlated with previous publications of the EarlyCDT Lung blood test.
The second paper looked at the use of two blood-based biomarker tests in tandem to reclassify the risk of indeterminate pulmonary nodules.
Researchers assessed the use of Nodify CDT (the US marketing name for EarlyCDT) with another test, called Nodify XL2.
The data revealed that “the combined testing strategy would have reduced delays in diagnosis of malignant nodules and helped reduce unnecessary procedures on benign nodules”.
In a statement, Oncimmune chief executive, Dr Adam Hill, said: "Whilst the EarlyCDT Lung blood test is underpinned by substantive evidence of its utility in IPN patients and reduction in unnecessary invasive procedures, I welcome this independent validation of the panel with the important PANOPTIC sample set, and confirmation of the utility of a combined rule-in and rule-out strategy in the US nodule clinic setting."